What Does Marketing Authorisation Mean for a Cannabis Medicine in the UK?
Since November 2018, discussions about cannabis as medicine have intensified across the United Kingdom. Headlines often leap to phrases like “cannabis is now legal” or “medical cannabis fully legalised,” but these claims can be misleading without context. A crucial aspect often overlooked is the concept of marketing authorisation—a formal process by which medicinal products receive approval for use in the UK. This post unpacks what marketing authorisation means for cannabis medicines, demystifies common confusions between Class and Schedule controls, and explains why, despite progress, cannabis remains tightly controlled under UK law.
We will also touch on why prescription of cannabis-based medicines is limited to specialists and why NHS access remains a challenge. Along the way, companies such as Nationwide Pharmacies, who play a vital role in dispensing licensed cannabis medicines, will be naturally referenced to give real-world grounding.
Understanding Marketing Authorisation: UK Medicines Regulator Approval Explained
Marketing authorisation is the UK medicines regulator’s formal approval that a medicine is safe, effective, and of high quality for its intended use. The regulatory body responsible is the Medicines and Healthcare products Regulatory Agency (MHRA).
Obtaining UK marketing authorisation means:
The medicine has undergone rigorous clinical trials and scientific scrutiny. Its manufacturing processes meet strict quality standards. Clear guidance is given on who can prescribe it and for what conditions. Packaging, labelling, and patient information are carefully regulated.
For cannabis medicines, marketing authorisation signals that a product is recognised within the official healthcare framework—not just tolerated or permitted under controlled drug laws.
UK Marketing Authorisation vs Licensed Medicine UK: What Does It Really Mean?
The phrase licensed medicine UK meaning often confuses readers. In the UK, a licensed medicine is a medicinal product that holds marketing authorisation. It is “licensed” in the sense of being formally approved by the MHRA, unlike unlicensed or “specials” medicines that may be compounded or imported without the same level of regulatory assessment.
For cannabis medicines, currently, there are a very limited number of products with marketing authorisation in the UK. For example, CBN-MS and CBD-based oral solutions have been granted licences by the MHRA for specific indications.
Pharmacies like Nationwide Pharmacies specialise in dispensing these licensed cannabis medicines and helping patients navigate the complex regulatory environment.
Takeaway: Marketing authorisation means a medicine is officially approved for safety, efficacy, and quality by the UK regulator, setting it apart from unlicensed cannabis products.
Class Vs Schedule: Clearing up Confusion in Cannabis Law
A common source of misunderstanding in UK cannabis regulation is the difference between Class and Schedule classifications under the Misuse of Drugs Act 1971 and Misuse of Drugs Regulations 2001.
Term Meaning Relevance to Cannabis Class Sets the overall level of control and penalties for possession/supply Cannabis is a Class B drug, meaning mid-level criminal penalties apply. Schedule Controls how a drug can be prescribed, manufactured, and imported/exported Cannabis-derived medicinal products fall under Schedule 1 or Schedule 2, depending on exact formulation.
After the 2018 legal change, cannabis-based products for medicinal use were reclassified, allowing specialist doctors to prescribe them legally. However, cannabis remains a Class B drug, so possession without prescription is still criminalised.
This distinction means that while cannabis medicines can be prescribed under certain conditions, the drug itself has not been “legalised” in the broader sense.
Takeaway: Class defines criminal penalties, while Schedule defines medical and pharmaceutical regulation—knowing the difference is key to understanding cannabis law in the UK.
What Changed in November 2018? The Legal Gateway for Medicinal Cannabis
November 2018 marked a milestone when the UK government rescheduled cannabis-based products for medicinal use. This meant licensed specialist doctors could prescribe certain cannabis medicines under controlled conditions.
Previously: Cannabis was classified entirely under Schedule 1, seen as having “no recognised medicinal value,” making prescriptions effectively impossible. Post-November 2018: Certain cannabis-based products moved to Schedule 2, enabling legal prescriptions for specified conditions by specialists.
Despite this progress, the law maintained strict access limits:
Prescriptions are restricted to consultant-grade doctors with expertise in relevant conditions. Only products with defined THC and CBD content—and consistent manufacturing quality—can be prescribed. Medicinal cannabis is not available for general practitioners or over-the-counter supply.
Nationwide Pharmacies became instrumental in supplying patients with licensed cannabis medicines following these regulatory changes, ensuring compliance with new prescribing and dispensing requirements.
Takeaway: The November 2018 changes opened a legal pathway for cannabis medicines but kept strict controls, making specialist prescribing and licensed medicines the norm.
Why Does Cannabis Remain Illegal Under the 1971 Act?
Although cannabis-based medicines are now prescribable, cannabis remains illegal for recreational use and possession without a prescription. The 1971 Misuse of Drugs Act is still in force.
Key reasons include:
Public Health Concerns — The government prioritises preventing misuse and dependency risks associated with recreational cannabis. Lack of Broad Scientific Consensus — While medicinal cannabis shows promise, more robust trials and data are needed for wider approval. International Obligations — The UK is party to UN drug control treaties that impose restrictions on cannabis.
Therefore, cannabis remains classified as a controlled substance, but medical use exceptions exist through specialist oversight and the limits set by Schedule 2 status.
Takeaway: Cannabis’s illegal status persists under the 1971 Act, balancing medicinal access with broader drug control policies.
Specialist-Only Prescribing and Limited NHS Access
One of the recurring frustrations for patients and healthcare practitioners is the difficulty accessing cannabis medicines via the NHS.
Why is prescribing restricted to specialists only?
Specialists such as neurologists and pain management experts have the expertise to assess risks and benefits within conditions like epilepsy or multiple sclerosis. The evidence base supporting cannabis medicines remains emerging; specialists are expected to apply clinical judgement. The MHRA’s stipulations and clinical guidelines reserve prescribing to ensure patient safety under monitoring.
Why is NHS access limited?
Cost considerations and lack of large-scale NHS-funded prescribing pathways. Clinical commissioning groups (CCGs) have varied policies; many have yet to endorse cannabis medicines routinely. Private prescriptions have filled the gap, with companies like Nationwide Pharmacies providing supply chains for licensed cannabis medicines by private prescription.
Patients may thus need to explore private options with specialist prescriptions to access these medicines, at least for now.
Takeaway: Specialist-only prescribing and limited NHS routes reflect the careful, cautious rollout of cannabis medicines in UK healthcare.
Conclusion: What Marketing Authorisation Means for Cannabis Medicine's Future
Marketing authorisation is the gateway to integrating cannabis medicines into mainstream UK healthcare. It differentiates fully licensed, high-standard medicines from unregulated cannabis products.
Since the 2018 legal changes, cannabis-based medicines have moved from theoretical exceptions to regulated prescriptions available via specialists, though challenges remain:
The ongoing confusion between Class and Schedule demands better patient education. Limited NHS access keeps many patients reliant on private prescriptions, impacting affordability. Continued research and clear regulatory pathways are needed for broader authorisation.
Pharmacies like Nationwide Pharmacies stand at the forefront by ensuring licensed cannabis medicines reach the patients who need them, operating within the UK’s complex regulatory environment.
Understanding marketing authorisation helps demystify what it means for cannabis medicine’s legal and medical status in the UK: it is not a blanket legalisation but a carefully controlled, evolving system prioritising safety, efficacy, and responsible patient access.
Final takeaway: UK marketing authorisation for cannabis medicines marks progress but within tight regulatory, legal, and clinical boundaries that patients and providers must navigate carefully.
